文献速递头颈部肿瘤放疗姑息放疗与转移瘤

颌面部及口腔按摩减轻鼻咽癌放疗所致严重口腔黏膜炎的随机对照II期试验

A randomized, controlled phase II trial of maxillofacial and oral massage in attenuating severe radiotherapy-induced oral mucositis and lipid metabolite changes in nasopharyngeal carcinoma.
PubMed 文献 · Radiother Oncol · 2021-07-31

该随机对照II期研究纳入158例接受调强放疗的鼻咽癌患者,1:1分为常规口腔护理组与加用颌面部及口腔按摩(MOM)组,主要终点为严重放射性口腔黏膜炎(SRTOM)发生率。结果显示MOM组SRTOM发生率低于对照组(26.3% vs 46.8%,P=0.008),且MOM不良事件轻微、可耐受,并伴随抗炎脂质代谢物升高。

要点

  • MOM组SRTOM发生率为26.3%,低于对照组的46.8%(P=0.008)。
  • MOM组RTOM和SRTOM发生时间均延迟、持续时间均缩短。
  • MOM相关3级及以上不良事件仅占1.3%,安全性可耐受。

核心结论

  • 颌面部及口腔按摩可显著降低鼻咽癌调强放疗患者严重放射性口腔黏膜炎的发生率。
  • MOM不良事件轻微且可耐受,并可能通过增强抗炎脂质代谢物发挥作用。

研究设计与样本

  • 随机对照II期研究,共158例接受调强放疗的鼻咽癌患者按1:1随机分为常规口腔护理和药物治疗组与加用MOM组。

主要发现

  • 治疗组SRTOM发生率为26.3%,低于对照组的46.8%(P=0.008)。
  • 治疗组RTOM中位发生时间较对照组长(12 vs 10天,HR 0.52,P<0.001),SRTOM中位发生时间亦较长(28.5 vs 19天,HR 0.5579,P=0.002)。
  • 治疗组RTOM中位持续时间较短(20.7 vs 24.7天,P=0.001),SRTOM中位持续时间亦较短(8.05 vs 13.08天,P<0.001)。
  • MOM期间仅1.3%的患者出现3级及以上不良事件。
  • MOM后抗炎脂质显著增加,尤其在10.6 Gy或更高剂量时。

临床怎么用

  • 对接受调强放疗的鼻咽癌患者,可在常规口腔护理和药物治疗基础上加用颌面部及口腔按摩以降低SRTOM风险。
  • MOM安全性可耐受,实施时仍需关注3级及以上不良事件的发生。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: This randomized controlled phase II study investigated the efficacy, safety and underlying mechanism of maxillofacial and oral massage (MOM) in nasopharyngeal carcinoma (NPC) patients receiving intensity-modulated radiotherapy. METHODS: A total of 158 NPC patients were randomly assigned 1:1 to routine oral care and medication (the control group) or that with additional MOM (the treatment group). The primary endpoint was the incidence of severe radiotherapy-induced oral mucositis (SRTOM). In addition, the time of initiation and duration of RTOM and SRTOM, adverse events, dynamic changes of lipid metabolites in peripheral blood were analyzed. RESULTS: Seventy-six patients in the treatment group and seventy-nine in the control group completed the trial. The incidence of SRTOM in the treatment group was lower than the control (26.3% vs. 46.8%, P = 0.008). The median initiation time to RTOM and SRTOM was significantly longer in the treatment group than the control (RTOM:12 vs 10 days, hazard ratio [HR] 0.52, P < 0.001; SRTOM: 28.5 vs 19 days, HR 0.5579, P = 0.002). While the median duration time of RTOM and SRTOM in the treatment group was shorter (RTOM: 20.7 vs 24.7 days, P = 0.001; SRTOM: 8.05 vs 13.08 days, P < 0.001). Only 1.3% of patients obtained grade 3 or higher adverse events during MOM. The anti-inflammatory lipids increased significantly after MOM, especially with 10.6 Gy or higher. CONCLUSION: MOM significantly attenuated the incidence of SRTOM in NPC patients. The adverse events of MOM were slight and tolerant. MOM enhanced anti-inflammatory lipid metabolites, which might be an underlying mechanism.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Yang G, Feng D, Li F, et al. A randomized, controlled phase II trial of maxillofacial and oral massage in attenuating severe radiotherapy-induced oral mucositis and lipid metabolite changes in nasopharyngeal carcinoma. Radiother Oncol. 2021. PMID: 34343545. doi:10.1016/j.radonc.2021.07.024

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。